Effects of serotonin-norepinephrine reuptake inhibitors on locomotion and prefrontal monoamine release in spontaneously hypertensive rats

European Journal of Pharmacology

Volumn 702, Issue 1-3, 2013, Pages 250-257

  Umehara, Masato ^a   Ago, Yukio ^a   Fujita, Kazumi ^a   Hiramatsu, Naoki ^a   Takuma, Kazuhiro ^a   Matsuda, Toshio ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Attention deficit hyperactivity disorder; Catecholamine; Prefrontal cortex; Serotonin norepinephrine reuptake inhibitor; Spontaneously hypertensive rat

Indexed keywords

ATOMOXETINE; CITALOPRAM; DESIPRAMINE; DOPAMINE; DULOXETINE; METHYLPHENIDATE; MILNACIPRAN; MONOAMINE; NORADRENALIN; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; VENLAFAXINE;

ACUTE DRUG ADMINISTRATION; ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BLOOD LEVEL; DRUG EFFECT; EXTRACELLULAR MATRIX; LOCOMOTION; MALE; MONOAMINE RELEASE; NONHUMAN; NORADRENALIN BLOOD LEVEL; OPEN FIELD TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONIN BLOOD LEVEL; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOPAMINE; MOTOR ACTIVITY; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; PREFRONTAL CORTEX; RATS; RATS, INBRED SHR; SEROTONIN;

EID: 84874513980     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.01.033     Document Type: Article

References (52)

1. Y. Ago, M. Sato, S. Nakamura, A. Baba, and T. Matsuda Lack of enhanced effect of antipsychotics combined with fluvoxamine on acetylcholine release in rat prefrontal cortex J. Pharmacol. Sci. 102 2006 419 422
2. 1 receptor activation Psychopharmacology 217 2011 377 386
3. B. Amini, P.B. Yang, A.C. Swann, and N. Dafny Differential locomotor responses in male rats from three strains to acute methylphenidate Int. J. Neurosci. 114 2004 1063 1084
4. Y. Arime, Y. Kubo, and I. Sora Animal models of attention-deficit/ hyperactivity disorder Biol. Pharm. Bull. 34 2011 1373 1376
5. A.F. Arnsten, and S.R. Pliszka Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders Pharmacol. Biochem. Behav. 99 2011 211 216
6. A.F. Arnsten The emerging neurobiology of attention deficit hyperactivity disorder: The key role of the prefrontal association cortex J. Pediatr. 154 2009 I-S43
7. L. Barrickman, R. Noyes, S. Kuperman, E. Schumacher, and M. Verda Treatment of ADHD with fluoxetine: a preliminary trial J. Am. Acad. Child Adolesc. Psychiatry 30 1991 762 767
8. E. Barron, P.B. Yang, A.C. Swann, and N. Dafny Adolescent and adult male spontaneous hyperactive rats (SHR) respond differently to acute and chronic methylphenidate (Ritalin) Int. J. Neurosci. 119 2009 40 58
9. C.W. Berridge, D.M. Devilbiss, M.E. Andrzejewski, A.F. Arnsten, A.E. Kelley, B. Schmeichel, C. Hamilton, and R.C. Spencer Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function Biol. Psychiatry 60 2006 1111 1120
10. Bilodeau, M., Simon, T., Beauchamp, M.H., Lespérance, P., Dubreucq, S., Dorée, J.P., Tourjman, S.V., Duloxetine in adults with ADHD: A randomized, placebo-controlled pilot study. J. Atten. Disord, 10.1177/1087054712443157, in press.
11. J. Biederman, T. Spencer, and T. Wilens Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder Int. J. Neuropsychopharmacol. 7 2004 77 97
12. F.P. Bymaster, J.S. Katner, D.L. Nelson, S.K. Hemrick-Luecke, P.G. Threlkeld, J.H. Heiligenstein, S.M. Morin, D.R. Gehlert, and K.W. Perry Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder Neuropsychopharmacology 27 2002 699 711
13. E. Carboni, G.L. Tanda, R. Frau, and G. Di Chiara Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals J. Neurochem. 55 1990 1067 1070
14. E. Davids, K. Zhang, N.S. Kula, F.I. Tarazi, and R.J. Baldessarini Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats J. Pharmacol. Exp. Ther. 301 2002 1097 1102
15. N. Easton, C. Steward, F. Marshall, K. Fone, and C. Marsden Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain Neuropharmacology 52 2007 405 414
16. S.V. Faraone, and J. Biederman What is the prevalence of adult ADHD? Results of a population screen of 966 adults J. Atten. Disord. 9 2005 384 391
17. R.L. Findling, L.L. Greenhill, N.K. McNamara, C.A. Demeter, L.A. Kotler, M.A. O'Riordan, C. Myers, and M.D. Reed Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder J. Child Adolesc. Psychopharmacol. 17 2007 433 445
18. R.R. Gainetdinov, W.C. Wetsel, S.R. Jones, E.D. Levin, M. Jaber, and M.G. Caron Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity Science 283 1999 397 401
19. 1 receptors J. Am. Acad. Child Adolesc. Psychiatry 49 2010 1011 1023
20. 3H]-tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites Neurosci. Lett. 157 1993 203 206
21. D.R. Gehlert, D.A. Schober, S.K. Hemrick-Luecke, J. Krushinski, J.J. Howbert, D.W. Robertson, R.W. Fuller, and D.T. Wong Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain Neurochem. Int. 26 1995 47 52
22. R.C. Kessler, L. Adler, R. Barkley, J. Biederman, C.K. Conners, O. Demler, S.V. Faraone, L.L. Greenhill, M.J. Howes, K. Secnik, T. Spencer, T.B. Ustun, E.E. Walters, and A.M. Zaslavsky The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication Am. J. Psychiatry 163 2006 716 723
23. T. Kihara, and M. Ikeda Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex J. Pharmacol. Exp. Ther. 272 1995 177 183
24. Y. Kitaichi, T. Inoue, T. Izumi, S. Nakagawa, A. Kato, and T. Koyama Subchronic milnacipran treatment increases basal extracellular noradrenaline concentrations in the medial prefrontal cortex of rats Eur. J. Pharmacol. 520 2005 37 42
25. S. Koch, S.K. Hemrick-Luecke, L.K. Thompson, D.C. Evans, P.G. Threlkeld, D.L. Nelson, K.W. Perry, and F.P. Bymaster Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats Neuropharmacology 45 2003 935 944
26. K. Koda, Y. Ago, Y. Cong, Y. Kita, K. Takuma, and T. Matsuda Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice J. Neurochem. 114 2010 259 270
27. J.S. Li, and Y.C. Huang Early androgen treatment influences the pattern and amount of locomotion activity differently and sexually differentially in an animal model of ADHD Behav. Brain Res. 175 2006 176 182
28. J. Mahmoudi-Gharaei, N. Dodangi, M. Tehrani-Doost, and T. Faghihi Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study Hum. Psychopharmacol. 26 2011 155 160
29. M.J. Millan, A. Gobert, F. Lejeune, A. Newman-Tancredi, J.M. Rivet, A. Auclair, and J.L. Peglion S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine J. Pharmacol. Exp. Ther. 298 2001 565 580
30. E.M. Miller, F. Pomerleau, P. Huettl, V.A. Russell, G.A. Gerhardt, and P.E. Glaser The spontaneously hypertensive and Wistar Kyoto rat models of ADHD exhibit sub-regional differences in dopamine release and uptake in the striatum and nucleus accumbens Neuropharmacology 63 2012 1327 1334
31. G. Paxinos, and C. Watson The Rat Brain in Sterotaxic Coordinates 2nd ed. 1986 Academic Press San Diego
32. G. Polanczyk, M.S. de Lima, B.L. Horta, J. Biederman, and L.A. Rohde The worldwide prevalence of ADHD: A systematic review and metaregression analysis Am. J. Psychiatry 164 2007 942 948
33. C.W. Popper Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder Child Adolesc. Psychiatr. Clin. N. Am. 9 2000 605 646 viii
34. T. Sagvolden, V.A. Russell, H. Aase, E.B. Johansen, and M. Farshbaf Rodent models of attention-deficit/hyperactivity disorder Biol. Psychiatry 57 2005 1239 1247
35. 1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex Eur. J. Pharmacol. 559 2007 155 160
36. L. Scahill, and M. Schwab-Stone Epidemiology of ADHD in schoolage children Child Adolesc. Psychiatr. Clin. N. Am. 9 2000 541 555 vii
37. S.R. Sesack, V.A. Hawrylak, C. Matus, M.A. Guido, and A.I. Levey Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter J. Neurosci. 18 1998 2697 2708
38. 3H]GBR 12935 as markers of dopamine innervation density in brain Synapse 25 1997 163 175
39. T. Spencer, J. Biederman, B. Coffey, D. Geller, M. Crawford, S.K. Bearman, R. Tarazi, and S.V. Faraone A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder Arch. Gen. Psychiatry 59 2002 649 656
40. T. Spencer, J. Biederman, K. Kerman, R. Steingard, and T. Wilens Desipramine treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome J. Am. Acad. Child Adolesc. Psychiatry 32 1993 354 360
41. A. Tamburella, V. Micale, C. Mazzola, S. Salomone, and F. Drago The selective norepinephrine reuptake inhibitor atomoxetine counteracts behavioral impairments in trimethyltin-intoxicated rats Eur. J. Pharmacol. 683 2012 148 154
42. G. Tanda, F.E. Pontieri, R. Frau, and G. Di Chiara Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine Eur. J. Neurosci 9 1997 2077 2085
43. M. Tatsumi, K. Groshan, R.D. Blakely, and E. Richelson Pharmacological profile of antidepressants and related compounds at human monoamine transporters Eur. J. Pharmacol. 340 1997 249 258
44. K.I. Ueno, H. Togashi, K. Mori, M. Matsumoto, S. Ohashi, A. Hoshino, T. Fujita, H. Saito, M. Minami, and M. Yoshioka Behavioural and pharmacological relevance of stroke-prone spontaneously hypertensive rats as an animal model of a developmental disorder Behav. Pharmacol. 13 2002 1 13
45. F.S. van den Bergh, E. Bloemarts, J.S. Chan, L. Groenink, B. Olivier, and R.S. Oosting Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder Pharmacol. Biochem. Behav. 83 2006 380 390
46. J. Waxmonsky Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness Curr. Opin. Pediatr. 15 2003 476 482
47. P. Weikop, T. Yoshitake, and J. Kehr Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain Eur. Neuropsychopharmacol. 17 2007 658 671
48. T.E. Wilens Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder J. Clin. Psychopharmacol. 28 2008 S46 S53
49. T.E. Wilens, J. Biederman, J. Prince, T.J. Spencer, S.V. Faraone, R. Warburton, D. Schleifer, M. Harding, C. Linehan, and D. Geller Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder Am. J. Psychiatry 153 1996 1147 1153
50. B.K. Yamamoto, and S. Novotney Regulation of extracellular dopamine by the norepinephrine transporter J. Neurochem. 71 1998 274 280
51. P.B. Yang, B. Amini, A.C. Swann, and N. Dafny Strain differences in the behavioral responses of male rats to chronically administered methylphenidate Brain Res. 971 2003 139 152
52. A.R. Zarinara, M.R. Mohammadi, N. Hazrati, M. Tabrizi, S.A. Rezazadeh, F. Rezaie, and S. Akhondzadeh Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial Hum. Psychopharmacol. 25 2010 530 535